DELRAY BEACH, Fla., Nov. 17, 2010 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or the “Company”) (Nasdaq:PSID) announced today that it has launched “The Wireless Body™” at the ID WORLD International Congress in Milan, Italy. The “Wireless Body” is an integrated, in vivo and external, smart healthcare communication system for diabetes management today and other disease management applications in the future. The “Wireless Body” is designed to enhance the management of diabetes by allowing disease management systems to communicate with each other and deliver solutions to patients seamlessly, enhancing the ability to deliver personalized medical solutions wirelessly.
Using its experience and expertise gained from developing the world’s first and only health-related implantable RFID (radio frequency identification) microchip cleared by the U.S. Food and Drug Administration, the Company has initiated the integration and development of other healthcare communication devices to communicate from within the body to outside of the body on an integrated platform: The “Wireless Body” by PositiveID. The “Wireless Body” also has the ability to identify medical devices, currently catheter ports, to allow them to communicate with PositiveID’s products to ensure proper medication dosages and safety for the patient from the port.
“We are excited to launch The Wireless Body as it expands the solutions we offer patients with diabetes to an entirely new level,” said Scott R. Silverman, Chairman and CEO of PositiveID. “Diabetes management requires an integrated solution, one that allows continuous monitoring and communication with devices that deliver solutions. We believe the ability to deliver an integrated solution wirelessly will enhance the quality of life for patients with diabetes and improve their compliance. The recent $24 million investment by Novartis into Proteus Biomedical’s ingestible wireless microchip highlights the opportunities in this sector and clearly validates the vision we began in this field over seven years ago.”
The Company’s technology has previously been used in Smart Healthcare by providing a vital electronic medical record and other wellness information to patients, caregivers and physicians. Most recently, PositiveID has evolved its implantable technology to focus on sensor applications through its GlucoChip™, a glucose-sensing microchip currently under development, and potentially other sensor applications based on its Patent No. 7,125,382 for an Embedded Bio-Sensor System. The GlucoChip is designed to communicate wirelessly to a handheld scanner outside of the body to deliver in vivo glucose readings without the need to draw blood.
Moving forward, the Company plans to integrate its wireless product portfolio with its patent-pending iglucose™ system, a wireless communication system for the transmission of glucose readings, to create automatic logs of glucose readings which can be delivered wirelessly to a third party (i.e. a caregiver or physician) from a handheld reader or traditional glucometer.